Binod Dhakal
@bhemato
Followers
2K
Following
2K
Media
175
Statuses
2K
Multiple myeloma; Immunotherapy
Milwaukee
Joined September 2014
RT @JoshuaRichterMD: Honored to be speaking in this group with @SagarLonialMD @andrew02114 and @bhemato Moderated by @szusmani #….
0
5
0
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
363
650
3K
RT @VJHemOnc: GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸. Explore practical considerations with the….
0
6
0
RT @Transplant_Doc: Talquetamab bridging allows rapid disease control with minimal grade toxicity, enabling treatment with BCMA CAR-T in he….
ashpublications.org
Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition
0
11
0
Fantastic US-German collaboration!Congrats to friends from US Immunotherapy Consortium and Max, David and @NicoGagelmann from Germany! @MedicalCollege @MCWCancerCenter.
🎉Finally out🎉. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity. @BloodPortfolio .#mmsm
2
6
27
Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database - Dhakal - 2025 - Cancer Medicine - Wiley Online Library
onlinelibrary.wiley.com
Background Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide-refractory disease. Methods We report re...
0
3
12
RT @mtmdphd: Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfol….
0
4
0
Excited to give a talk on zevor-cel and other novel CAR-T in MM; “Academic Exchange” Shanghai,China! @MedicalCollege @MCWCancerCenter
3
3
28
Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma | Blood Advances | American Society of Hematology @MedicalCollege @MCWCancerCenter
ashpublications.org
Long-term survival (LTS) in multiple myeloma (MM), defined as survival of ≥10 years post-diagnosis following a single line of therapy, is an increasingly o
0
6
18
Congrats @DrRakeshPopat on your great presentation! Very promising early results that could be disruptive in the clinic!.
@EHA plenary session - @DrRakeshPopat presenting JNJ-5322 - a trispecific antibody in relapse refractory myeloma. A new potential step change for RR MM
1
2
7
All oral combination with sonrotoclax+dex in 70% TCE pts with ORR 81% at the highest dose in t(11;14) RRMM @MedicalCollege @MCWCancerCenter
3
9
19
RT @RahulBanerjeeMD: #ASCO25 And another one!.@JCO_ASCO: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated….
0
20
0
Fantastic results! Great news for the patients!.
Authors: Sundar Jagannath, @TomBmt133, @YiLinMDPhD, @CohenAd_MMdoc, @NoopurRajeMD, Myo Htut, @abhinav_deol, Mounzer Agha, @BerdejaJesus, @LesokhinMd, Jessica Liegel, @Dr_AdrianaRossi, Alex Lieberman-Cribbin, @szusmani, @bhemato, Samir Parekh, Andrzej Jakubowiak, @PlasmaCellPete.
0
1
8
RT @VincentRK: The most impressive myeloma abstract at #ASCO25 . Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate….
0
40
0
RT @Blood_Cancers: This weekend, catch up on the latest podcasts and interviews from #HOPLive!. Don't miss these invigorating discussions o….
0
2
0
EHA Library - The official digital education library of European Hematology Association (EHA)! Highly impressive activity of this novel bcl2 inhibitor in MM; excited to present poster at EHA and oral@at Lugano @MCWCancerCenter
library.ehaweb.org
EHA Library; Dhakal B. Jun 13 2025; 4160128;
1
0
1